Brokerages Set Alphatec Holdings, Inc. (NASDAQ:ATEC) Price Target at $17.00

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $17.00.

ATEC has been the topic of several research analyst reports. Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Friday, August 30th. Stifel Nicolaus lowered their price target on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Lake Street Capital lowered their price objective on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Wells Fargo & Company cut their target price on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Finally, Piper Sandler lowered their price objective on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st.

Alphatec Trading Up 3.2 %

ATEC stock opened at $9.70 on Friday. The company has a market cap of $1.38 billion, a P/E ratio of -7.58 and a beta of 1.31. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34. The business has a fifty day moving average of $6.12 and a 200-day moving average of $8.44. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Insider Transactions at Alphatec

In related news, Director David M. Demski purchased 50,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were acquired at an average cost of $5.67 per share, for a total transaction of $283,500.00. Following the acquisition, the director now owns 288,441 shares of the company’s stock, valued at $1,635,460.47. The trade was a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Large investors have recently added to or reduced their stakes in the stock. Net Worth Advisory Group acquired a new position in shares of Alphatec in the third quarter worth $76,000. Comerica Bank lifted its holdings in Alphatec by 64.8% in the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after purchasing an additional 2,534 shares in the last quarter. Van ECK Associates Corp raised its stake in Alphatec by 57.0% during the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after purchasing an additional 6,998 shares during the period. Tempus Wealth Planning LLC acquired a new position in shares of Alphatec during the 3rd quarter valued at $107,000. Finally, Atria Investments Inc boosted its position in Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after buying an additional 1,460 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.